Graphite Bio Inc
NASDAQ:GRPH
Intrinsic Value
Graphite Bio, Inc. operates as a clinical-stage gene editing company. [ Read More ]
The intrinsic value of one GRPH stock under the Base Case scenario is 3.16 USD. Compared to the current market price of 22.26 USD, Graphite Bio Inc is Overvalued by 86%.
Valuation Backtest
Graphite Bio Inc
Run backtest to discover the historical profit from buying and selling GRPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Graphite Bio Inc's business.
What risks and challenges
does Graphite Bio Inc face in the near future?
Summarize the latest earnings report
of Graphite Bio Inc.
Provide P/E
for Graphite Bio Inc and its competitors.
Balance Sheet Decomposition
Graphite Bio Inc
Current Assets | 188m |
Cash & Short-Term Investments | 184.3m |
Other Current Assets | 3.8m |
Non-Current Assets | 435k |
PP&E | 321k |
Other Non-Current Assets | 114k |
Current Liabilities | 4.8m |
Accounts Payable | 250k |
Accrued Liabilities | 4.5m |
Non-Current Liabilities | 77k |
Other Non-Current Liabilities | 77k |
Earnings Waterfall
Graphite Bio Inc
Revenue
|
0
USD
|
Operating Expenses
|
-73.1m
USD
|
Operating Income
|
-73.1m
USD
|
Other Expenses
|
-51.5m
USD
|
Net Income
|
-124.7m
USD
|
Free Cash Flow Analysis
Graphite Bio Inc
What is Free Cash Flow?
GRPH Profitability Score
Profitability Due Diligence
Graphite Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Graphite Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GRPH Solvency Score
Solvency Due Diligence
Graphite Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Graphite Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GRPH Price Targets Summary
Graphite Bio Inc
According to Wall Street analysts, the average 1-year price target for GRPH is 7 USD .
Ownership
GRPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GRPH Price
Graphite Bio Inc
Average Annual Return | -52.42% |
Standard Deviation of Annual Returns | 32.53% |
Max Drawdown | -94% |
Market Capitalization | 1.3B USD |
Shares Outstanding | 58 240 000 |
Percentage of Shares Shorted | 0.28% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2021-06-25. The firm is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The firm's lead product candidate, GPH101, is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin (HgbA) expression. Its pipeline includes multiple programs, such as GPH102, for beta-thalassemia and GPH201, for X-linked severe combined immunodeficiency syndrome (XSCID), which is its gene replacement technology; GPH301 for Gaucher disease and an early-stage research program for alpha-1 antitrypsin (AAT) deficiency, which is its targeted gene insertion technology, and multiple undisclosed programs in both hematopoietic stem cells (HSCs) and other cell types.
Contact
IPO
Employees
Officers
The intrinsic value of one GRPH stock under the Base Case scenario is 3.16 USD.
Compared to the current market price of 22.26 USD, Graphite Bio Inc is Overvalued by 86%.